

References for CEQUA® (cyclosporine ophthalmic solution) 0.09% Dry Eye Disease Awareness Patient Discussion Brochure

1. Schechter BA, Urbieta M, Bacharach J, et al. Effect of OTX-101 on patients with dry eye disease at day 14 of treatment: ocular surface endpoint results from the phase 2b/3 clinical trial. *Clin Ophthalmol*. 2022;16:4145-4151.
2. Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. *Ophthalmology*. 2019;126(9):1230-1237.
3. Malhotra R, Devries DK, Luchs J, et al. Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca: A pooled analysis of phase 2b/3 and phase 3 studies. *Cornea*. 2019;38:1259-1265.
4. Tauber J, Schechter BA, Bacharach J, et al. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. *Clin Ophthalmol*. 2018;12:1921-1929.
5. Karpecki P, Barghout V, Schenkel B, et al. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis. *BMC Ophthalmol*. 2023;23(1):443. doi:10.1186/s12886-023-03174-y.
6. Mohamed HB, Abd El-Hamid BN, Fathalla D, Fouad EA. Current trends in pharmaceutical treatment of dry eye disease: A review. *Eur J Pharm Sci*. 2022;175:106206. doi:10.1016/j.ejps.2022.106206
7. CEQUA [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2022.
8. Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.
9. US Patent 9,937,225 B2.

Current as of: June 17, 2024

© 2024 Sun Pharmaceutical Industries, Inc. All rights reserved. CEQUA is a registered trademark of Sun Pharmaceutical Industries Limited. All other trademarks are the property of their respective owners.

PM-US-CQA-1595 06/2024